- Covance experts to present best practices for improving drug safety and reducing R&D time, cost -
PRINCETON, N.J., June 16 /PRNewswire-FirstCall/ -- Covance Inc. is pleased to announce the complete list of experts scheduled to present at the Drug Information Association's (DIA) 45th Annual Meeting from June 21-25, 2009 in San Diego, Calif.
The DIA Annual Meeting is the biopharmaceutical industry's largest, longest running, global, multidisciplinary event. This year's program offers learning opportunities for everyone and features the biggest names from industry, regulatory, and academia.
Building on the conference theme, "Better Medicines: Improving Safety with Every Step," Covance experts will present best practices for improving safety while reducing the time and cost of drug development, including:
June 22, 2009:
- "Innovation at a CRO: A Strategic Management Platform to Enhance Overall Value of a Client's Portfolio"
10:30 a.m. | Speaker: Krish Ghosh, PhD, vice president, resource management
- "Issues and Challenges Associated with the PSUR Process"
1:30 p.m. | Session Chair: Robert Bader, PharmD, senior director, product safety, periapproval services
- "Improving Safety with Expanded Training Options for Physicians in Early Phases of Clinical Research"
1:30 p.m. | Speaker: Russ Dixon, MD, medical director, early clinical development
- "EDC Front to Back: Streamline Processes End-to-End for True Operational Benefit"
3:30 p.m. Page: 1 2 3 4 5 Related biology technology :1
. Covance Elects John McCartney to Companys Board of Directors2
. Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets3
. Covance Opens New Clinical Development Offices in Chile, Peru and Expands Argentina Office4
. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc5
. Covance Increases Early Clinical Footprint in Europe with Acquisition of Swiss-Based Early Clinical Development Site6
. Covance Purchases Equity Stake in Caprion Proteomics7
. Covance and Lilly Finalize 10-Year, $1.6 Billion Strategic R&D Collaboration8
. Covance Decides to Pursue Its Original Preclinical Strategy in China9
. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China10
. Covance to Present at The R.W. Baird 2008 Growth Stock Conference11
. Covance to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference